Given MoonLake Immunotherapeutics' recent announcements of significant improvements in their Nanobody® sonelokimab clinical trials, coupled with strong regulatory feedback and positive analyst outlooks, I believe MLTX has been overbought, making it a prime candidate for a short position as expectations may be priced in.